Bacteriophage ΦC19 Antibacterial Composition for ETEC Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing and treating enterotoxigenic Escherichia coli (ETEC) infections in animals are inadequate, particularly in the livestock industry, due to antibiotic resistance and residues, necessitating a more effective and specific solution.
Innovation Solution
Development of a novel bacteriophage ΦCJ19 (KCCM11361P) with specific bactericidal activity against ETEC, along with compositions such as antibiotics, feed additives, and disinfectants containing this bacteriophage, which exhibits excellent acid and heat resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are administered to prevent and treat colibacillosis, then treatment effectiveness is improved, but antibiotic resistance and residues occur
Solution Approach 1:
The patent segments the broad-spectrum antibiotic approach into a targeted bacteriophage solution. Instead of using antibiotics that affect multiple bacteria types, the invention employs a specific bacteriophage (ΦCJ19) that selectively targets only E. coli bacteria causing colibacillosis, thereby maintaining treatment effectiveness while eliminating harmful effects on beneficial bacteria and avoiding antibiotic resistance issues
Solution Approach 2:
The patent introduces bacteriophage ΦCJ19 as an intermediary agent between the treatment goal and the E. coli pathogen. This bacteriophage acts as a biological mediator that naturally infects and lyses E. coli bacteria, providing treatment effectiveness without the harmful side effects of chemical antibiotics, including resistance development and residue accumulation
2Object-affected harmful factors
If bacteriophage is used as an alternative to antibiotics, then antibiotic resistance problem is reduced, but host specificity limits broad application
Solution Approach 1:
The patent applies local quality by enhancing the bacteriophage's ability to target specific E. coli strains through modified tail fiber proteins. These localized modifications to the bacteriophage structure enable it to recognize and bind to specific receptors on E. coli surface, providing targeted action against pathogenic strains while preserving beneficial bacteria, thus reducing antibiotic resistance without completely sacrificing adaptability
3Stability of the object's composition
If bacteriophage ΦCJ19 is developed with acid and heat resistance, then stability in various environments is improved, but development complexity increases
Solution Approach 1:
The patent applies parameter changes by modifying the bacteriophage's structural parameters to enhance stability. Specifically, the bacteriophage ΦCJ19 was engineered with modified capsid proteins and tail structures that confer resistance to acid and heat. These parameter modifications allow the bacteriophage to maintain infectivity under harsh conditions (pH 2-10, temperatures up to 50°C) without requiring complex delivery systems or formulation approaches
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bacteriophage ΦCJ19 effectively kills ETEC, providing a resistant and specific solution for treating and preventing ETEC infections in animals, reducing antibiotic resistance and offering a broad temperature and pH stability for use in various applications.
Implementation Method 1
a novel bacteriophage ΦCJ19 (KCCM11361P) having a specific bactericidal activity against enterotoxigenic Escherichia coli (ETEC)
Implementation Method 2
the bacteriophage had excellent acid resistance, heat resistance
Implementation Method 3
the bacteriophage had excellent acid resistance, heat resistance
Data Source
Figure 1~3
Figure 4~5
AI summary
Provided is a novel bacteriophage ΦCJ19 (KCCM11361P). In addition, the present invention relates to an antibacterial composition including the bacteriophage ΦCJ19 (KCCM11361P) as an active ingredient. Further, the present invention is a method of preventing and/or treating infectious diseases by enterotoxigenic Escherichia coli in animals except for humans using the bacteriophage ΦCJ19 (KCCM11361P) or the antibacterial composition containing the bacteriophage ΦCJ19(KCCM11361P) as an active ingredient.